Connection

Yuki Kageyama to Urothelium

This is a "connection" page, showing publications Yuki Kageyama has written about Urothelium.
Connection Strength

0.337
  1. Platelet-to-Lymphocyte Ratio Predicts the Efficacy of Pembrolizumab in Patients With Urothelial Carcinoma. Anticancer Res. 2022 Feb; 42(2):1131-1136.
    View in: PubMed
    Score: 0.192
  2. Loss of uroplakin III expression is associated with a poor prognosis in patients with urothelial carcinoma of the upper urinary tract. BJU Int. 2006 Jun; 97(6):1322-6.
    View in: PubMed
    Score: 0.065
  3. PPARgamma ligands suppress proliferation of human urothelial basal cells in vitro. J Cell Physiol. 2002 Jun; 191(3):310-9.
    View in: PubMed
    Score: 0.049
  4. The impact of preoperative serum C-reactive protein on the prognosis of patients with upper urinary tract urothelial carcinoma treated surgically. BJU Int. 2007 Aug; 100(2):269-73.
    View in: PubMed
    Score: 0.017
  5. Impaired p63 expression associates with poor prognosis and uroplakin III expression in invasive urothelial carcinoma of the bladder. Clin Cancer Res. 2003 Nov 15; 9(15):5501-7.
    View in: PubMed
    Score: 0.014
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.